However,in several recent PROMISE case,woman participants who had begun efavirenz-basee standard of care treatment have presented to routine study visits with generally asymptomatic grade 3 to 4 hepatotoxicity(ALT>500),most of whom had resolution with discontinuation of efavirenz, the liver enzyme hepatotoxic recurred.